Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.52USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
282,226
52-wk High
$5.44
52-wk Low
$3.20

Chart for

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $409.77
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

GlaxoSmithKline adult shingles vaccine wins U.S. approval

The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.

20 Oct 2017

GlaxoSmithKline adult shingles vaccine wins U.S. approval

Oct 20 The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.

20 Oct 2017

BRIEF-Agenus files for mixed shelf of up to $250 million

* Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​ Source text - (http://bit.ly/2yzul1n) Further company coverage:

18 Oct 2017

'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

13 Sep 2017

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

Sept 13 A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

13 Sep 2017

BRIEF-Agenus Inc Q2 loss per share $0.32

* Agenus reports second quarter 2017 financial results and provides corporate update

03 Aug 2017

Earnings vs. Estimates